利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

213 条记录 (耗时 0.015 秒)

    BIOSYNTHESIS OF HIF
    97.
    发明公开
    BIOSYNTHESIS OF HIF 审中-公开
    生物合成的HIF

    公开(公告)号：EP1539190A1

    公开(公告)日：2005-06-15

    申请号：EP03742127.8

    申请日：2003-06-20

    申请人： THE GENERAL HOSPITAL CORPORATION ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

    发明人： HAUPERT, Garner T., Jr. ,  GULLANS, Steven, R.

    IPC分类号： A61K31/70 ,  A61K38/00 ,  A61K39/395 ,  G01N33/53

    CPC分类号： G01N33/743 ,  A61K38/00 ,  C12Q1/26 ,  C12Q1/533 ,  G01N2333/4704 ,  G01N2333/90245 ,  G01N2800/52

    摘要： The present invention relates to a method of identifying an agent (e.g., petide, small molecule) that alters (partially, completely ) the activity (function, expression) of HIF. In one embodiment, the method of identifying an agent that alters (e.g., inhibits, enhances) the activity of HIF comprises contacting a molecule in the HIF biosynthetic pathway (e.g., a precursor of HIF, such as a steroid precursor; an enzyme) with an agent to be assessed and determining whether the activity of the molecule (function, expression) is altered in the presence of the agent when compared to the activity of the molecule in the absence of the agent. The invention is also related method of treatment using such agents; and methods of monitoring the biosynthetic pathway of OLC/HIF. In particular, the invention is related to agent, treatments, and diagnostics for diseases such a hypertension and heart failure.

    METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY
    98.
    发明公开
    METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY 有权
    VERFAHREN ZUR MESSUNG DER INDUZIERBARKEIT VON MENSCHLICHEM CYP3A

    公开(公告)号：EP1496118A1

    公开(公告)日：2005-01-12

    申请号：EP03717587.4

    申请日：2003-04-15

    申请人： Yamazoe, Yasushi ,  DAIICHI PURE CHEMICALS CO., LTD.

    发明人： YAMAZOE, Yasushi ,  NAGATA, Kiyoshi

    IPC分类号： C12N15/09 ,  C12Q1/02

    CPC分类号： C12Q1/6897 ,  C12Q1/02 ,  C12Q1/26 ,  G01N33/5008 ,  G01N33/5023 ,  G01N33/5067 ,  G01N2333/90245 ,  G01N2333/90251 ,  G01N2500/04 ,  G01N2500/10

    摘要： A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.
    The present invention ensures convenient and accurate evaluation of human CYP3A inducibility upon administration of a test drug to a human subject, providing accurate evaluation in terms of the efficacy of the test drug, occurence of side effects, disappearance of the drug effect, etc.

    摘要翻译： 一种在给药试验药物时测量人CYP3A诱导率的方法，其特征在于，在含有试验药物的培养基中培养的非人动物或受试药物培养的人群受病毒感染（A） 和（B）; 病毒（A）是腺病毒，其用作载体并通过掺入可检测的报告基因和位于人CYP3A基因的非翻译区内的至少3个人PXR结合区和作为腺病毒的病毒（B）而工程改造 被用作载体并通过掺入人PXR cDNA而工程化; 并且随后在非人动物或培养的人细胞中测定报道基因的表达水平。 本发明确保了在将受试药物施用于人受试者时对人CYP3A诱导能力的方便和准确的评估，在试验药物的功效方面提供准确的评价，副作用的发生，药物作用的消失 等等

    TUMOUR-SPECIFIC P450 PROTEIN
    99.
    发明授权
    TUMOUR-SPECIFIC P450 PROTEIN 失效
    肿瘤特异性P450蛋白

    公开(公告)号：EP0856157B1

    公开(公告)日：2004-11-24

    申请号：EP96931897.1

    申请日：1996-09-25

    申请人： The University Court of The University of Aberdeen ,  University of Massachusetts

    发明人： MELVIN, William, Thomas ,  MURRAY, Graeme, Ian ,  BURKE, Michael, Danny ,  GREENLEE, William, Frank

    IPC分类号： G01N33/574 ,  C07K14/80

    CPC分类号： A61K38/44 ,  C12N9/0077 ,  C12Q1/26 ,  C12Y114/14001 ,  G01N33/57492 ,  G01N2333/90245 ,  G01N2500/00

    摘要： The discovery that CYP1B1 protein is detectable in a wide range of human cancers of different histogenetic types, but is not detectable in non-cancerous tissues, gives rise to diagnostic methods for detecting tumours based on this protein as a marker, and to the possibility of tumour therapies involving the protein. A diagnostic method may include the steps of: (a) obtaining from a patient a tissue sample to be tested for the presence of cancer cells; (b) producing a prepared sample in a sample preparation process; (c) contacting the prepared sample with an antibody that reacts with human CYP1B1 protein; and (d) detecting binding of the antibody to CYP1B1 protein in the prepared sample.

    摘要翻译： CYP1B1蛋白在不同组织发生类型的广泛人类癌症中可检测到但在非癌性组织中检测不到的发现提供了基于该蛋白作为标志物检测肿瘤的诊断方法， 涉及蛋白质的肿瘤治疗。 诊断方法可以包括以下步骤：（a）从患者获得待检测的组织样品中癌细胞的存在; （b）在样品制备过程中制备制备的样品; （c）将制备的样品与能与人CYP1B1蛋白质反应的抗体接触; 和（d）检测制备的样品中抗体与CYP1B1蛋白的结合。